Review of recent trials of chemotherapy for advanced breast cancer: The Taxanes

European Journal of Cancer

Volumn 33, Issue 13, 1997, Pages 2183-2193

  Demons, M ^a   Leahy, M ^a   Valle, J ^a   Jayson, G ^a   Ranson, M ^a   Howell, A ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; THIOTEPA;

ADVANCED CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FLUID RETENTION; HUMAN; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0031409092     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00260-8     Document Type: Article

References (99)

1. Vermorken JB, et al. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Semin Oncol 1995, 22 (4 Suppl. 8), 16-22.
2. Gelmon KA. Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. Semin Oncol 1995, 22 (5 Suppl. 12), 117-122.
3. Seidman AD, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995, 13(5), 1152-1159.
4. Seidman AD, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996, 14(6), 1877-1884.
5. Gianni L, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995, 13(11), 2688-2699.
6. Dombernowsky P, et cd. Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 1995, 22 (6 Suppl. 15), 13-17.
7. Dombernowsky P, et al. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 1996, 23 (1 Suppl. 1), 13-18.
8. Holmes FA. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. Semin Oncol 1995, 22 (4 Suppl. 8), 9-15.
9. Amadori D, et al. A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer. Semin Oncol 1996, 23 (1 Suppl. 1), 19-23.
10. Wasserheit C, et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 1996, 14(7), 1993-1999.
11. Nabholtz JM, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. JClin Oncol 1996, 14(6), 1858-1867.
12. Dieras V, et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 1995, 22 (4 Suppl. 8), 33-39.
13. Chevallier B, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995, 13(2), 314-322.
14. Ravdin PM, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer [see comments]. J Clin Oncol 1995, 13(12), 2879-2885.
15. Hudis CA, et al. Phase II and pharmacologie study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996, 14(1), 58-65.
16. Valero V, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer [see comments]. J Clin Oncol 1995, 13(12), 2886-2894.
17. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol 1995, 22 (3 Suppl. 6), 101-104.
18. Davidson NG. Single-agent paclitaxel at first relapse following adjuvant chemotherapy for breast cancer. Semin Oncol 1995, 22 (6 Suppl. 14), 2-6.
19. Seidman AD, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. y Clin Oncol 1995, 13(10), 2575-2581.
20. Abrams JS, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial, J Clin Oncol 1995, 13(8), 2056-2065.
21. Tolcher AW, et al. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996, 14(4), 1173-1184.
22. Gianni L, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995, 87(15), 1169-1175.
23. Sledge GW Jr, et al. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol 1995, 22 (3 Suppl. 6), 105-108.
24. Luck HJ, et al. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 1996, 23 (1 Suppl. 1), 33-36.
25. Conte PF, et al. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer. Semin Oncol 1996, 23 (1 Suppl. 1), 28-32.
26. Fisherman JS, et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 1996, 14(3), 774-782.
27. Catimel G, et al. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety. Semin Oncol 1996, 23 (1 Suppl. 1), 24-27.
28. Gelmon K, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996, 14, 1185-1191.
29. O'Reilly SE, Gelmon KA. Biweekly paclitaxel and cisplatin: a phase I/II study in the first-line treatment of metastatic breast cancer. Semin Oncol 1995, 22 (3 Suppl. 6), 109-111.
30. Tolcher AW, Gelmon KA. Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer. Semin Oncol 1995, 22 (4 Suppl. 8), 28-32.
31. Klaassen U, et al. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer. Semin Oncol 1996, 23 (1 Suppl. 1), 44-47.
32. Klaassen U, et al. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis. Semin Oncol 1995, 22 (6 Suppl. 14), 7-11.
33. Paul DM, et al. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience. Semin Oncol 1996, 23 (1 Suppl. 1), 48-52.
34. Kennedy M, Donehower M, Rowinsky E. Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide. Semin Oncol 1995, 22 (4 Suppl. 8), 23-27.
35. Kennedy M, et al. Phase I and pharmacologie study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 1996, 14(3), 783-791.
36. Tolcher A, et al. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. JClin Oncol 1996, 14(1), 95-102.
37. Tolcher AW. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 1996, 23 (1 Suppl. 1), 37-43.
38. Hainsworth JD, et al. Paclitaxel with mitoxantrone fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial. J Clin Oncol 1996, 14(5), 1611-1616.
39. Stemmer SM, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996, 14(5), 1463-1472.
40. Hudis C, et al. Sequential adjuvant therapy with doxorubicin/ paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 1995, 22 (6 Suppl. 15), 18-23.
41. Adachi I, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996, 73(2), 210-216.
42. Fumoleau P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996, 7(2), 165-171.
43. Trudeau ME, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996, 14(2), 422-428.
44. van Oosterom AT. Docetaxel (taxotere): an effective agent in the management of second-line breast cancer. Semin Oncol 1995, 22 (6 Suppl. 13), 22-28.
45. Swain S, Honig S, Watson L. Phase II trial of paclitaxel (Taxol) as first line chemotherapy for metastatic breast cancer. Proc. ASCO 1995, 14, Abs227.
46. Bonneterre J, Tubiana-Hulin M, Chollet Ph, et al. Taxol (paclitaxel) 225mg/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with metastatic breast cancer. Proc ASCO 1996, 15, Abs 179.
47. Geyer C, Green S, Moinpour C, et al. A phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast. Proc ASCO 1996, 15, Abs 92.
48. Currow D, D'Souza D, Clarke H, et al. Paclitaxel in heavily pretreated breast cancer. Proc ASCO 1995, 14, Abs 237.
49. 2 by 3 hour infusion without G-CSF as a second line therapy in patients with metastatic breast cancer. Eur J Cancer 1995, 31A, Suppl. 5, Abs 378.
50. Cognetti F, Aloe A, Nardi M, et al. Low activity of paclitaxel in patients with metastatic breast cancer resistant to anthracyclines. Proc ASCO 1996, 15, Abs 227.
51. Luftner D, Mergenthaler H-G, Grunewald R, et al. Paclitaxel in a weekly fractionated schedule in advanced breast cancer. Proc ASCO 1996, 15, Abs 266.
52. RisebergD, Cowan K, Zujewski J, etal. Phase I study of a 14 day paclitaxel infusion in patients with advanced malignancies. Proc ASCO 1995, 14, Abs 1576.
53. Mamounas E, Brown A, Fisher B, et al. 3 hour high-dose taxol infusion in advanced breast cancer: an NSABP phase II study. Proc ASCO 1995, 15, Abs 206.
54. Perrtz T, Sulkes A, Chollet P, et al. A multicenter, randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer 1995, 31A, Abs 345.
55. Holmes FA, Valero V, Walters R, et al. Phase III trial of paclitaxel administered over 3 or 96 hours for metastatic breast cancer. Proc ASCO 1996, 15, Abs 91.
56. Gianni L, Capri G, Tarenzi E, et al. Efficacy and cardiac effects of 3-H paclitaxel + bolus doxorubicin in women with untreated metastatic breast carcinoma. Proc ASCO 1996, 15, Abs 128.
57. Tjulandin S, Stenina M, Toropov A, et al. Phase II study of taxol followed by doxorubicin as induction chemotherapy in advanced breast cancer patients. Ann Oncol 1996, 7 (Suppl. 1), Abs 323.
58. Schwartsmann G, Menke C, Caleffi M, et al. Phase II trial of taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer. Proc ASCO 1996, 15, Abs 168.
59. Frassineti G, Zoli W, Tienghi A, et al. Phase I/II study of sequential combination of paclitaxel and doxorubicin in the treatment of advanced breast cancer. Proc ASCO 1996, 15, Abs 103.
60. Luck H, Thomssen C, Dubois A, et al. Phase II study of paclitaxel and 4-epi-doxorubicin as first-line therapy in patients with metastatic breast cancer. Proc ASCO 1996, 15, Abs 147.
61. Conte P, Michelotti A, Baldini E, et al. Epirubicin plus paclitaxel, a highly active combination devoid of significant cardiotoxicity in the treatment of metastatic breast cancer. Proc ASCO 1996. 15, Abs 138.
62. Cazap E, Ventriglia M, Rubio M, et al. Taxol plus doxorubicin in the treatment of metastatic breast cancer in ambulatory patients. Proc ASCO 1996, 15, Abs 248.
63. Lalisang R, Wils J, Mortier J, et al. Dose intensification of epirubicin and paclitaxel with G-CSF in metastatic breast cancer. Proc ASCO 1996, 15, Abs 62.
64. Di-Constanzo F, Sdrobolini A, Bilancia D, et al. Phase I/II trial of mitoxantrone and taxol in advanced breast cancer. Proc ASCO 1996, 15, Abs 220.
65. Jacobs S, Stoller R, Earle M, et cd. Phase I study of sequential adriamycin and taxol with neupogen support in advanced support in advanced breast cancer. Proc ASCO 1996, 15, Abs 55.
66. Berry J, Ezzat A, El-Warith A, et al. Sequential taxol/platinum: pilot in metastatic breast cancer. Proc ASCO 1996, 15, Abs 243.
67. Browne MJ, Kennedy T, Cummings F, et al. Phase II study of sequential taxol and cisplatin for the treatment of metastatic breast cancer. Proc ASCO 1996, 15, Abs 245.
68. Sparano J, Neuberg D, Glick J, et al. A phase II trial of biweekly paclitaxel and cisplatin in patients with advanced breast carcinoma. Proc ASCO 1996, 15, Abs 121.
69. McCaskill-Stevens W, Ansan R, Fisher W, et al. Phase II study of biweekly cisplatin and paclitaxel in the treatment of metastatic breast cancer. Proc ASCO 1996, 15, Abs 144.
70. Frazein A, Wassenheit C, Hochster H, et al. High rate of peripheral neuropathy may limit paclitaxel and cisplatin combination in women with advanced breast cancer. Proc ASCO 1995, 14, Abs 145.
71. Aravantinos G, Athanassiadis A, Giannakakis T, et al. Paclitaxel and carboplatin with G-CSF support in advanced breast cancer resistant to anthracyclines. EurJCancer 1996, 32A (Suppl. 2), 48.
72. Klaassen U, Wilke H, Strumberg D, et al. Paclitaxel combinations with weekly high dose 5-FU/Folinic acid and cisplatin in the treatment of metastatic breast cancer. There is a possible role of combining paclitaxel with anthracycline non cross resistant chemotherapeutic agents in first and second line treatment. Eur J Cancer 1996, 32A (Suppl. 2), 48.
73. Zaniboni A, Guarinoni L, Distefano L, et al. Taxol, folinic acid and fluorouracil as second line treatment for advanced breast cancer: a pilot study. Proc ASCO 1996, 15, Abs 202.
74. Pagani O, Sessa C, De Jong J, et al. Dose-finding study of taxol and cyclophosphamide in advanced breast cancer. Eur J Cancer 1995, 31A (Suppl. 5), Abs 925.
75. Tkaczuk KH, Tait NS, Pearl P. Preliminary report of a phase II study with paclitaxel and ifosfamide in patients with metastatic breast cancer. Ann Oncol 1996, 7 (Suppl. 1), Abs 324.
76. Murad A, Tinoco L, Schwartsmann G, et al. Phase II trial of the use of taxol and ifosfamide in heavily pretreated patients with metastatic breast cancer. Proc ASCO 1996, 15, Abs 52.
77. Fennelly D, Gilewski T, Hudis C, et al. Phase I trial of sequential edatrexate followed by paclitaxel: a design based on in-vitro synergy in patients with advanced breast cancer. Proc ASCO 1995, 14, Abs 105.
78. Tubiana-Hulin M, Catimel G, Bonneterre J, et al. Phase I/II study of taxol in combination with epirubicin and cyclophosphamide without G-CSF as a first line treatment of metastatic breast carcinoma. Proc ASCO 1996, 15, Abs 265.
79. Nicholson B, Paul D, Hande K, et al. A phase II trial: paclitaxel 5-fluorouracil and leucovorin in metastatic breast cancer. Proc ASCO 1996, 15, Abs 72.
80. Kourousis C, Kakolyris S, Cheras P, et al. A preliminary report of an active salvage chemotherapy combining vinorelbine, paclitaxel and CDDP in anthracyclin-resistant advanced breast cancer. Proc ASCO 1996, 15, Abs 258.
81. Shilder LE, Albain KS, Hantel T, et al. Phase I trial of taxol, ifosphamide, cisplatin in patients with solid tumours. Proc ASCO 1995, 14, Abs 14.
82. Zimmermann TM, Mick R, Grinblatt DL, et al. High dose cyclophosphamide, thiotepa, with escalating continuous infusion taxol and autologous stem cell rescue for metastatic breast cancer. Proc ASCO 1995, 14, Abs 977.
83. Cagnoni PJ, Shpall EJ, Matthes S, et al. Paclitaxel containing high-dose chemotherapy with autologous haematopoietic progenitor cell support. Symposium-New Directions in Anti-Cancer Chemotherapy, Paris, 1996, 22-23.
84. Vukelja S, Baker W, Burrell L. et al. High dose taxol, cyclophosphamide, and cisplatin with stem cell support in treatment of metastatic breast cancer. Proc ASCO 1995, 14, Abs 185.
85. Glück S, Arnold A, Dulude H, et al. High dose cyclophosphamide, mitoxantrone, and paclitaxel with blood progenitor cell support for the treatment of metastatic breast cancer. Proc ASCO 1996, 15, Abs 212.
86. Broun E, Sledge G, Walsh W, et al. Dose escalation of taxol with high dose carboplatin/cyclophosphamide and PBPC support in stage IV breast cancer. Proc ASCO 1996, 15, Abs 103.
87. Gianni L, Demicheli R, Moliterni A, et al. Pilot study of primary chemotherapy with doxorubicin-paclitaxel in women with T2-T3 or locally advanced breast carcinoma. Proc ASCO 1996, 15, Abs 129.
88. Hudis C, Seidman A, Raptis G, et al. Sequential doxorubicin, paclitaxel, and cyclophosphamide in women with resected breast cancer and ≥ 4 lymph nodes: preliminary results. Proc ASCO 1995, 14, Abs 152.
89. Zujewski J, Danforth D, Noone M, et al. Short course, dose intensive, fourteen day cycle of doxorubicin and cyclophosphamide followed by infusional paclitaxel in the treatment of high risk primary breast cancer. Proc ASCO 1996, 15, Abs 145.
90. Broun E, Petruruska P, Dunphy F, et al. Taxol plus carboplatin/ cyclophosphamide and peripheral blood stem cell support in stage II/III breast cancer. Proc ASCO 1996, 15, Abs 1002.
91. Schwartzberg L, Berch R, Weaver C, et al. Neoadjuvant chemotherapy with or without paclitaxel and high dose chemotherapy with peripheral blood progenitor cell support for locally advanced breast cancer. Proc ASCO 1996, 15, Abs 160.
92. Van Oosterom A, Dieras V, Tubiana-Hulin M, et al. Taxotere in previously treated patients with metastatic breast carcinoma: stratification for anthracycline resistance. Proc ASCO 1996, 15, Abs 231.
93. Valero V, Burns H, Jones S, et al. Multicentre pilot study of taxotere in Taxol-resistant metastatic breast cancer. Proc ASCO 1996, 15, Abs 95.
94. Vorobiof D, Chasen M, Moeken R. Phase II trial of single agent docetaxel in previously treated patients with advanced breast cancer. Proc ASCO 1996, 15, Abs 185.
95. Trandafir L, Chahine A, Spielman M, et al. Efficacy of taxotere in advanced breast cancer patients not eligible for further anthracyclines. Proc ASCO 1996, 15, Abs 86.
96. Huinink W, Dubbelman R, Hiemstra A, et al. Phase I study of docetaxel alternating with epirubicin and cyclophosphamide in an escalated and accelerated schedule by the concomitant use of lenograstim. Proc ASCO 1996, 15, Abs 229.
97. Enomoto K, Abe R, Fukuda M, et al. Phase 1 study of combination docetaxel with cyclophosphamide in the treatment of metastatic breast cancer. Eur J Cancer 1996, 32A (Suppl. 2), 47.
98. Bourgeois H, Gruia G, Dieras V, et al. Docetaxel in combination with doxorubicin as first line chemotherapy of metastatic breast cancer: a phase I dose finding study. Proc ASCO 1996, 15, Abs 259.
99. Bishop J, Dewar J, Tattersall M, et al. A randomised phase III study of Taxol vs CMFP in untreated patients with metastatic breast cancer. Proc ASCO 1996, 15, Abs 107.